Hepatitis C-related membranoproliferative glomerulonephritis in the era of direct antiviral agents
Related Experiment Video
Updated: Nov 16, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Walid Ahmed Ragab Abdelhamid1, Ali Shendi1, Mahmoud Zahran1
1Zagazig University, Faculty of Medicine, Internal Medicine Department, Zagazig, Egypt.
Abstract:
Membranoproliferative glomerulonephritis (MPGN) is the most typical Hepatitis C virus (HCV)-associated glomerulopathy, and the available data about the utilization of direct-acting antivirals (DAA) in HCV-associated glomerulonephritis is inadequate. We evaluated the renal and viral response in two cases of HCV-related MPGN; the first caused by cryoglobulinemia while the second was cryoglobulin-negative. Both patients received immunosuppression besides DAA in different regimens. They achieved partial remission but remained immunosuppression-dependent for more than 6 months after DAA despite sustained virological response, which enabled safer but incomplete immunosuppression withdrawal. Both patients were tested for occult HCV in peripheral blood mononuclear cells and found to be negative. Hence, the treatment of HCV-related MPGN ought to be according to the clinical condition and the effects of drug therapy. It is important to consider that renal response can lag behind the virological response.
Insights
Direct-acting antivirals (DAA) show promise for Hepatitis C virus (HCV)-related membranoproliferative glomerulonephritis (MPGN), but patients may remain immunosuppression-dependent post-treatment. Renal response can lag behind viral response in these complex cases.
Area of Science:
- Nephrology
- Hepatology
- Virology
Background:
- Membranoproliferative glomerulonephritis (MPGN) is frequently associated with Hepatitis C virus (HCV).
- Limited data exists on direct-acting antiviral (DAA) efficacy in HCV-associated glomerulonephritis.
- HCV-related MPGN can manifest with or without cryoglobulinemia.
Purpose of the Study:
- To evaluate renal and viral response in two cases of HCV-related MPGN treated with DAAs.
- To assess the impact of DAA therapy on immunosuppression requirements in HCV-related MPGN.
- To investigate the relationship between virological and renal response following DAA treatment.
Main Methods:
- Case study analysis of two patients with HCV-related MPGN (one cryoglobulinemic, one cryoglobulin-negative).
- Treatment involved direct-acting antivirals (DAA) combined with immunosuppression.
- Assessment of renal function, viral load, and immunosuppression dependence post-DAA therapy.
Main Results:
- Both patients achieved partial remission with DAA and immunosuppression.
- Sustained virological response was observed, but immunosuppression dependence persisted for over 6 months.
- Incomplete immunosuppression withdrawal was necessary despite negative occult HCV testing in peripheral blood mononuclear cells.
Conclusions:
- Treatment for HCV-related MPGN should be individualized based on clinical status and drug response.
- Renal recovery may lag significantly behind viral clearance after DAA therapy.
- HCV-related MPGN management requires careful consideration of ongoing immunosuppression needs.
Related Concept Videos
Retrovirus Life Cycles
Subviral Agents
Retroviruses
Nephrotic Syndrome I : Introduction

